Your browser doesn't support javascript.
loading
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
Liu, Hien Duong; Ahn, Kwang Woo; Hu, Zhen-Huan; Hamadani, Mehdi; Nishihori, Taiga; Wirk, Baldeep; Beitinjaneh, Amer; Rizzieri, David; Grunwald, Michael R; Sabloff, Mitchell; Olsson, Richard F; Bajel, Ashish; Bredeson, Christopher; Daly, Andrew; Inamoto, Yoshihiro; Majhail, Navneet; Saad, Ayman; Gupta, Vikas; Gerds, Aaron; Malone, Adriana; Tallman, Martin; Reshef, Ran; Marks, David I; Copelan, Edward; Gergis, Usama; Savoie, Mary Lynn; Ustun, Celalettin; Litzow, Mark R; Cahn, Jean-Yves; Kindwall-Keller, Tamila; Akpek, Gorgun; Savani, Bipin N; Aljurf, Mahmoud; Rowe, Jacob M; Wiernik, Peter H; Hsu, Jack W; Cortes, Jorge; Kalaycio, Matt; Maziarz, Richard; Sobecks, Ronald; Popat, Uday; Alyea, Edwin; Saber, Wael.
Afiliación
  • Liu HD; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio. Electronic address: liuh@ccf.org.
  • Ahn KW; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Hu ZH; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Hamadani M; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Nishihori T; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Wirk B; Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
  • Beitinjaneh A; Department of Hematology and Oncology, University of Miami Sylvester Cancer Center, Miami, Florida.
  • Rizzieri D; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
  • Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina.
  • Sabloff M; Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Canada.
  • Olsson RF; Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
  • Bajel A; Department of Haematology and Bone Marrow Transplant, Royal Melbourne Hospital, Victoria, Australia.
  • Bredeson C; The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Daly A; Department of Medicine, Tom Baker Cancer Centre, Calgary, Canada; Department of Oncology, Tom Baker Cancer Centre, Calgary, Canada.
  • Inamoto Y; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Majhail N; Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
  • Saad A; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
  • Gupta V; Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Gerds A; Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Malone A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Tallman M; Leukemia Service, Department of Medicine, Memorial Sloan, New York, New York.
  • Reshef R; Blood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York.
  • Marks DI; Pediatric Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
  • Copelan E; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina.
  • Gergis U; Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
  • Savoie ML; Division of Hematology and Hematologic Malignancies, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
  • Ustun C; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota.
  • Litzow MR; Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, Minnesota.
  • Cahn JY; Department of Hematology, University Hospital, Grenoble, France.
  • Kindwall-Keller T; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.
  • Akpek G; Stem Cell Transplantation and Cellular Therapy Program, Banner MD Anderson Cancer Center, Gilbert, Arizona.
  • Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Aljurf M; Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia.
  • Rowe JM; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Wiernik PH; Our Lady of Mercy Medical Center, Bronx, New York.
  • Hsu JW; Division of Hematology and Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, Florida.
  • Cortes J; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kalaycio M; Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Maziarz R; Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
  • Sobecks R; Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Popat U; Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, Texas.
  • Alyea E; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Saber W; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Biol Blood Marrow Transplant ; 23(5): 767-775, 2017 May.
Article en En | MEDLINE | ID: mdl-28115276
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for patients with chronic myelomonocytic leukemia (CMML); however, few data exist regarding prognostic factors and transplantation outcomes. We performed this retrospective study to identify prognostic factors for post-transplantation outcomes. The CMML-specific prognostic scoring system (CPSS) has been validated in subjects receiving nontransplantation therapy and was included in our study. From 2001 to 2012, 209 adult subjects who received HCT for CMML were reported to the Center for International Blood and Marrow Transplant Research. The median age at transplantation was 57 years (range, 23 to 74). Median follow-up was 51 months (range, 3 to 122). On multivariate analyses, CPSS scores, Karnofsky performance status (KPS), and graft source were significant predictors of survival (P = .004, P = .01, P = .01, respectively). Higher CPSS scores were not associated with disease-free survival, relapse, or transplantation-related mortality. In a restricted analysis of subjects with relapse after HCT, those with intermediate-2/high risk had a nearly 2-fold increased risk of death after relapse compared to those with low/intermediate-1 CPSS scores. Respective 1-year, 3-year, and 5-year survival rates for low/intermediate-1 risk subjects were 61% (95% confidence interval [CI], 52% to 72%), 48% (95% CI, 37% to 59%), and 44% (95% CI, 33% to 55%), and for intermediate-2/high risk subjects were 38% (95% CI, 28% to 49%), 32% (95% CI, 21% to 42%), and 19% (95% CI, 8% to 29%). We conclude that higher CPSS score at time of transplantation, lower KPS, and a bone marrow graft are associated with inferior survival after HCT. Further investigation of CMML disease-related biology may provide insights into other risk factors predictive of post-transplantation outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielomonocítica Crónica / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielomonocítica Crónica / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos